 |
|
|
| |
Perspectives on the Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators From Patients Receiving Cabotegravir + Rilpivirine Long-Acting Injectable Treatment (CAB + RPV LA): Interim Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL)
|
| |
| |
EACS 2021 Oct 27-30
Laurent Hocqueloux1, Cassidy Gutner2, Rebecca DeMoor3, Martin Gill3, Rekha Trehan3, Ronald D'Amico2, Susan Tomkins3, Melanie Schroeder4, Gilda Bontempo5, Mounir Ait-Khaled4, Monica Hadi6, Savita Bakhshi Anand6, Emma L. Low6, Eliette Jeanmaire7, María Crusells Canales8, Linos Vandekerckhove9, Fabrice Bonnet10, Julián Olalla Sierra11, Maggie Czarnogorski2
1CHR d'Orléans, Hôpital de la Source, Orléans, France; 2ViiV Healthcare, Research Triangle Park, NC, United Kingdom; 3GlaxoSmithKline, Brentford, United Kingdom; 4ViiV Healthcare, Brentford, United Kingdom; 5ViiV Healthcare, Branford, CT, United States; 6Evidera, London, United Kingdom;
7CHRU de Nancy, Hôpitaux de Brabois, Vanduvre-lès-Nancy, France; 8Hospital Clinico Lozano Blesa, Zaragoza, Spain; 9UZ Gent, Gent, Belgium; 10CHU de Bordeaux, Hôpital Saint André, Bordeaux, France; 11Hospital Costa del Sol, Marbella, Spain
|
| |
|
|
|
|
|
